PMID- 29705266
OWN - NLM
STAT- MEDLINE
DCOM- 20190101
LR  - 20190101
IS  - 1873-2399 (Electronic)
IS  - 0301-472X (Linking)
VI  - 63
DP  - 2018 Jul
TI  - Elevated serum BDNF levels are associated with favorable outcome in CLL patients: 
      Possible link to CXCR4 downregulation.
PG  - 17-21.e1
LID - S0301-472X(18)30174-7 [pii]
LID - 10.1016/j.exphem.2018.04.005 [doi]
AB  - Increased chemokine C-X-C receptor 4 (CXCR4) expression is related to unfavorable 
      outcome in chronic lymphocytic leukemia (CLL). Brain-derived neurotrophic factor 
      (BDNF) is a neuronal growth factor that has been shown previously to interact 
      with CXCR4 in neuronal cells. Here, we studied the in vitro effect of BDNF on 
      CXCR4 expression and chemotaxis toward stromal derived factor-1 (SDF-1) in 
      freshly isolated CLL cells. We also explored the correlations between serum BDNF 
      levels in CLL patients and disease characteristics and clinical course. 
      Incubation of CLL cells with recombinant BDNF (50 ng/mL) resulted in a 
      downregulation of CXCR4 surface expression and atenuated chemotaxis toward SDF-1. 
      Higher serum BDNF levels were associated with a mutated immunoglobulin heavy 
      chain variable (IGHV) gene, an early clinical stage, and a stable clinical 
      course. Our findings suggest that increased circulating blood BDNF may be 
      associated with a favorable effect in CLL. However, the exact mechanism of this 
      favorable effect should be investigated further.
CI  - Copyright (c) 2018 Elsevier Ltd. All rights reserved.
FAU - Azoulay, David
AU  - Azoulay D
AD  - Hematology Unit, Galilee Medical Center, Nahariya & Bar-Ilan University Faculty 
      of Medicine Safed, Israel. Electronic address: davidA@gmc.gov.il.
FAU - Herishanu, Yair
AU  - Herishanu Y
AD  - Department of Hematology, Sourasky Medical Center and Sackler Faculty of 
      Medicine, Tel-Aviv University, Tel-Aviv, Israel.
FAU - Shapiro, Mika
AU  - Shapiro M
AD  - Department of Hematology, Sourasky Medical Center and Sackler Faculty of 
      Medicine, Tel-Aviv University, Tel-Aviv, Israel.
FAU - Brandshaft, Yarden
AU  - Brandshaft Y
AD  - Hematology Unit, Galilee Medical Center, Nahariya & Bar-Ilan University Faculty 
      of Medicine Safed, Israel.
FAU - Suriu, Celia
AU  - Suriu C
AD  - Hematology Unit, Galilee Medical Center, Nahariya & Bar-Ilan University Faculty 
      of Medicine Safed, Israel.
FAU - Akria, Luiza
AU  - Akria L
AD  - Hematology Unit, Galilee Medical Center, Nahariya & Bar-Ilan University Faculty 
      of Medicine Safed, Israel.
FAU - Braester, Andrei
AU  - Braester A
AD  - Hematology Unit, Galilee Medical Center, Nahariya & Bar-Ilan University Faculty 
      of Medicine Safed, Israel.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180426
PL  - Netherlands
TA  - Exp Hematol
JT  - Experimental hematology
JID - 0402313
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (CXCL12 protein, human)
RN  - 0 (CXCR4 protein, human)
RN  - 0 (Chemokine CXCL12)
RN  - 0 (Immunoglobulin Variable Region)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Receptors, CXCR4)
RN  - 0 (Recombinant Proteins)
RN  - 7171WSG8A2 (BDNF protein, human)
RN  - EC 2.7.10.1 (Receptor, trkB)
RN  - EC 2.7.10.1 (tropomyosin-related kinase-B, human)
SB  - IM
MH  - Brain-Derived Neurotrophic Factor/*blood/genetics/pharmacokinetics/physiology
MH  - Chemokine CXCL12/pharmacology
MH  - Chemotaxis/drug effects
MH  - Down-Regulation/drug effects
MH  - Gene Expression Regulation, Leukemic/drug effects
MH  - Gene Rearrangement, B-Lymphocyte, Heavy Chain
MH  - Genes, Immunoglobulin
MH  - Humans
MH  - Immunoglobulin Variable Region/genetics
MH  - Kaplan-Meier Estimate
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*blood/genetics/mortality/pathology
MH  - Membrane Glycoproteins/biosynthesis/genetics
MH  - Neoplasm Proteins/biosynthesis/*blood/genetics/physiology
MH  - Platelet Count
MH  - Prognosis
MH  - Receptor, trkB/biosynthesis/genetics
MH  - Receptors, CXCR4/*biosynthesis/genetics
MH  - Recombinant Proteins/pharmacology
MH  - Tumor Cells, Cultured
EDAT- 2018/05/01 06:00
MHDA- 2019/01/02 06:00
CRDT- 2018/04/30 06:00
PHST- 2018/02/11 00:00 [received]
PHST- 2018/04/12 00:00 [revised]
PHST- 2018/04/18 00:00 [accepted]
PHST- 2018/05/01 06:00 [pubmed]
PHST- 2019/01/02 06:00 [medline]
PHST- 2018/04/30 06:00 [entrez]
AID - S0301-472X(18)30174-7 [pii]
AID - 10.1016/j.exphem.2018.04.005 [doi]
PST - ppublish
SO  - Exp Hematol. 2018 Jul;63:17-21.e1. doi: 10.1016/j.exphem.2018.04.005. Epub 2018 
      Apr 26.